Comparative Pharmacology
Head-to-head clinical analysis: INVEGA TRINZA versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA TRINZA versus SEZABY.
INVEGA TRINZA vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
Terminal elimination half-life: 3 to 6 months (mean 118 days) due to slow dissolution from intramuscular depot; clinical context: steady state reached after 3 injections every 3 months.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Renal: 59-80% as unchanged drug and metabolites; fecal: 6-15%; biliary: minimal.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic